The effect of pirfenidone on the mortality risk score in IPF

• Register: JPRN
• Last refreshed on: 17 October 2023
• Main ID: JPRN-UMIN000008541
• Date of registration: 30/07/2012
• Prospective Registration: Yes
• Primary sponsor: Department of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine
• Public title: The effect of pirfenidone on the mortality risk score in IPF
• Scientific title: The effect of pirfenidone on the mortality risk score in IPF - The effect of pirfenidone on the mortality risk score in IPF
• Date of first enrolment: 2012/07/30
• Target sample size: 20
• Recruitment status: Complete: follow-up complete
• URL: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010041
• Study type: Interventional
• Study design: Single arm Non-randomized
• Phase: Not applicable

Countries of recruitment

Japan

Contacts

• Name: Osamu Nishiyama, MD
• Affiliation: Kinki University Faculty of Medicine Department of Respiratory Medicine and Allergology

• Name: Osamu Nishiyama, MD
• Affiliation: Kinki University Faculty of Medicine Department of Respiratory Medicine and Allergology

Key inclusion & exclusion criteria

Inclusion criteria:
Exclusion criteria: 1. Diagnosis of malignancies 2. Unable to undergo pulmonary function test and 6-min walk test 3. Already taking pirfenidone 4. A history of severe toxicity of pirfenidone 5. Undergoing long-term oxygen therapy at rest

Age minimum: 20years-old
Age maximum: Not applicable
Gender: Male and Female

Health Condition(s) or Problem(s) studied

idiopathic pulmonary fibrosis

Intervention(s)

pirfenidone

Primary Outcome(s)

mortality risk score

Secondary Outcome(s)

1. pulmonary function test 2. 6-min walk test 3. dyspnea 4. chest HRCT findings

Source(s) of Monetary Support

none

Ethics review

Status: YES
Approval date:
Contact:

Results

• Results available: Yes
• Date Completed: 18/12/2014